Search

Displaying results 4541 - 4550 of 10000 in total
  1. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    Aceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274273] It has also been studied in the treatment of presbyopia, a common age-related vision loss where the crystalline lens hardens and loses elasticity, impairing near vision.

    Synonyms: 3-Acetoxyquinuclidine
  2. Drug

    Bezisterim

    go.drugbank.com/drugs/DB05212
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.

    Categories: Drugs Used in Diabetes
  4. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    Oxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

    Synonyms: 4-HMP, 4-hydroxyephedrine
  5. Pathway

    Viomycin Action Pathway

    smpdb.ca/view/SMP0126771
    Drug action

    Viomycin is an antibiotic used to treat Mycobacterium tuberculosis and binds to the ribosome displacing structures leading to inhibition of protein synthesis. It binds to the interface between helix 44 of the small ribosomal subunit and ...

    Drugs: Viomycin
    Enzymes: 16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA
  6. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. … [A40025] From the LAMA group, revefenacin is the first once-daily nebulized LAMA treatment.[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  7. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.

    Synonyms: Immunoglobulin g1, anti-(human tissue factor pathway inhibitor) (human monoclonal pf-06741086 .gamma.1-chain), disulfide with human monoclonal pf-06741086 .lambda.-chain, dimerProducts: Hympavzi 150 mg/mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet)
  8. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma … of the limbs as the product Beromun.

  9. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form. … Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome.

    Synonyms: 2-amino-1-ethanethiol, β-MEAProducts: CYSTAGON ® 150 MG, CYSTAGON ® 50 MG CAPSULAS
  10. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with heavy menstrual bleeding, anemia, abdominal pain and pressure, bloating, increased urinary frequency

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsSynonyms: 3-(5-((2,3-difluoro-6-methoxyphenyl)methoxy)-2-fluoro-4-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(3,4-d)pyrimidine-5-carboxylic acid, Thieno(3,4-d)pyrimidine-5-carboxylic acid, 3-(5-((2,3-difluoro-6-methoxyphenyl)methoxy)-2-fluoro-4-methoxyphenyl)-1,2,3,4-tetrahydro-2,4-dioxo-